Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Natig Gassanov (1) , Nasser Semmo (2) , Mariam Semmo (3) , Amir M. Nia (1) , Uwe Fuhr (4) , Fikret Er (1)

1 Department of Internal Medicine III
2 Department of Medicine II
3 Department of Nephrology
4 Department of Pharmacology

Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of VR-mediated vasoconstriction and VR-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.

Mots clés: Vasopressin; Vaptans; Hyponatremia; Heart failure; SIADH

Domaines: Pharmacologie

Natig Gassanov, Nasser Semmo, Mariam Semmo, Amir M. Nia, Uwe Fuhr, et al.. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). European Journal of Clinical Pharmacology, 2011, 67 (4), pp.333-346. ⟨10.1007/s00228-011-1006-7⟩. ⟨hal-00671229⟩